MariMed Q3 revenue misses analyst expectations

Marimed

05/11/2025 22:32

Overview

MariMed Q3 revenue misses analyst expectations, adjusted EBITDA also missed estimates

Company reports sequential growth in wholesale and retail revenues for Q3

MariMed expands brand distribution to Maine, Pennsylvania, and New York

Outlook

Company anticipates distribution in Pennsylvania and New York to begin in 2026

MariMed plans to launch hemp-derived THC products in Rhode Island by early 2026

Result Drivers

WHOLESALE EXPANSION - Sequential growth in wholesale revenues driven by expansion in Massachusetts and Illinois

NEW MARKET ENTRY - Expansion into Maine, Pennsylvania, and New York as part of strategic growth plan

COST MANAGEMENT - Improved profitability through disciplined cost management and operational efficiencies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$40.80 mln
$42.40 mln (3 Analysts)
Q3 Adjusted Net loss
Slight Miss*
-$1.50 mln
-$1.49 mln (2 Analysts)
Q3 GAAP Net loss
-$2.90 mln
Q3 Adjusted EBITDA
Miss
$5.10 mln
$5.89 mln (3 Analysts)
Q3 Gross Margin
40.00%
Q3 Adjusted EBITDA Margin
13.00%
Q3 Adjusted Gross Margin
41.00%


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the drug retailers peer group is "buy"

Wall Street's median 12-month price target for MariMed Inc is $0.23, about 53.8% above its November 4 closing price of $0.10

Press Release: ID:nGNX8Ytv7s

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)